Global double whammy for fast-growing Arecor
A global top 20 pharmaceutical giant is leveraging proprietary formulation technology from Arecor, the Chesterford Research Park-based company.
Under the collaboration, for which no figures are being released, Arecor will leverage its ArestatTM technology to develop superior liquid formulations of its partner’s proprietary products.
The partner will fund the development work and has the option to acquire the rights to the formulation and associated Intellectual Property under a technology licensing model.
Arecor CEO Dr Sarah Howell said the partnership further demonstrated the value of Arecor’s ArestatTM technology platform in delivering superior therapeutic treatments that were otherwise not achievable.
She said: “This new partnership further strengthens our pipeline of commercial projects within our formulation technology business. Our commercial relationships with pharmaceutical partners represent the opportunity to showcase both our technology and scientific expertise.
“With the option to grant an exclusive licence to the formulation developed, we potentially have an ongoing role to support our pharmaceutical partner in the development of their superior therapeutic products.”
To cap a momentous week, Arecor also revealed dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes.
The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels. This is to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypo and hyperglycaemia.
The double-blind, randomised, three-way cross over Phase I clinical study will compare the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments.
The trial is being conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research and preliminary results are expected towards the end of the year.
Dr Howell said: “The initiation of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes.”